Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
Rhea-AI Summary
Dare Bioscience (NASDAQ: DARE) will host its First Quarter 2026 financial results conference call and live webcast on May 14, 2026 at 4:30 p.m. ET to review results for the quarter ended March 31, 2026 and provide a company update. The webcast will be archived through May 28, 2026.
Dial-in numbers, conference ID 2531472, and webcast access are available in the Investors section of the company's website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – DARE
On the day this news was published, DARE declined 7.91%, reflecting a notable negative market reaction. Argus tracked a trough of -12.5% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $46.01M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DARE fell 3.36% while close biotech peers showed mixed moves (e.g., TENX -4.15%, NRSN -7.99%, ALLR +3.58%). With no momentum flags and no same-day peer news, trading appears more stock-specific than sector-driven.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 20 | Earnings call scheduling | Neutral | +4.6% | Announced full year 2025 results call and webcast timing and access details. |
| Nov 06 | Earnings call scheduling | Neutral | -1.6% | Set Q3 2025 results call date, time, and webcast/phone participation info. |
| Aug 07 | Earnings call scheduling | Neutral | -9.7% | Announced Q2 2025 financial results call and webcast for investors. |
| May 06 | Earnings call scheduling | Neutral | -4.0% | Scheduled Q1 2025 results and company update conference call and webcast. |
| Mar 24 | Earnings call scheduling | Neutral | -0.5% | Planned full year 2024 financial results call with company update presentation. |
Similar conference/earnings call scheduling headlines have produced modest, mixed price reactions, with an average move of -2.25% across the last five such events.
Over the past year, Daré has repeatedly scheduled conference calls and webcasts to discuss quarterly and annual results, typically at 4:30 p.m. ET. These “conferences,earnings” announcements, including events on March 31, 2025 and March 26, 2026, framed updates on commercialization plans and pipeline progress. Price reactions around these scheduling notices have been mixed, averaging about -2.25%, suggesting limited but sometimes noticeable trading impact when such calls are announced.
Historical Comparison
In the past, five Daré “conferences,earnings” scheduling headlines produced an average move of -2.25%. Today’s -3.36% reaction is moderately more negative but directionally consistent with that history.
The company has established a recurring pattern of scheduling quarterly and annual results calls with accompanying updates, providing structured checkpoints on commercialization and pipeline progress.
Market Pulse Summary
The stock moved -7.9% in the session following this news. A negative reaction despite this being a routine scheduling notice fits prior “conferences,earnings” headlines, which averaged a -2.25% move. With shares at $3.16, still above the 200-day MA of $1.98, any pronounced decline could reflect positioning or profit-taking rather than information in the announcement itself. Recent regulatory filings detailing financing structures and governance changes may also frame how investors interpret upcoming Q1 2026 results.
AI-generated analysis. Not financial advice.
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2026, to review its financial results for the quarter ended March 31, 2026 and to provide a company update.
To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2531472. The live webcast can be accessed under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior to the call to register and to download and install any necessary software. The webcast will be archived in the same section of the company's website and available for replay until May 28, 2026.
About Daré Bioscience
Daré Bioscience is a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, pelvic pain to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs.
For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to real, evidence-based solutions continues to lag. Daré was founded to change that. As a female-led health biotech company, Daré is accelerating the development of credible, science-based solutions that meet the high standards of clinical rigor – randomized, controlled trials; validated endpoints; peer-reviewed publications; and current Good Manufacturing Practice (cGMP) requirements.
To learn more about Daré’s mission to deliver differentiated therapies for women and its innovation pipeline, please visit www.darebioscience.com.
Daré Bioscience leadership has been named on the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma and Daré's CEO has been honored as one of Fierce Pharma’s Most Influential People in Biopharma for Daré’s contributions to innovation and advocacy in the women’s health space.
Daré may announce material information about its finances, products and product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, products and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré’s website.
Contacts:
Daré Bioscience Investor Relations
innovations@darebioscience.com
Source: Daré Bioscience, Inc.
